These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20005697)

  • 1. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
    Pond GR; Armstrong AJ; Wood BA; Leopold L; Galsky MD; Sonpavde G
    BJU Int; 2012 Dec; 110(11 Pt B):E461-8. PubMed ID: 22520631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
    Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
    Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
    Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
    Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
    J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
    Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
    J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
    Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
    Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Clin Genitourin Cancer; 2012 Dec; 10(4):239-45. PubMed ID: 23000202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in hormone-refractory prostate cancer.
    de Wit R
    BJU Int; 2008 Mar; 101 Suppl 2():11-5. PubMed ID: 18307687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
    Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
    Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
    Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
    J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.